サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629167

バイオシミラーインスリンの世界市場：種類別・適応症別・流通チャネル別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)

Biosimilar Insulin Market, By Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
バイオシミラーインスリンの世界市場：種類別・適応症別・流通チャネル別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)
出版日: 2024年12月04日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

バイオシミラーインスリンの市場規模は、2023年に26億9,087万米ドルとなり、2024年から2032年にかけて16.44%のCAGRで拡大

バイオシミラーインスリンの市場力学

世界の糖尿病有病率の増加が市場需要を促進

糖尿病有病率の増加が世界のバイオシミラーインスリン市場の需要を促進しています。糖尿病の研究開発への投資が増加し、先発インスリンの特許が切れるにつれて、バイオシミラーインスリンが牽引役となっています。世界中で5億人以上が糖尿病に罹患しており、費用対効果の高いインスリン製剤に対するニーズが急増しています。しかし、規制上の課題や臨床での限定的な受け入れが、長期的な普及の障壁となっています。それとは逆に、長い歴史を持つ先発品インスリン製剤の特許切れが、革新的な新規バイオシミラーインスリン製剤の需要を促進し、メーカーに成長機会をもたらすと期待されています。

バイオシミラーインスリン市場：主な考察

弊社リサーチアナリストの分析によると、世界市場は予測期間 (2024-2032年) に約16.44%のCAGRで毎年成長すると予測されています。

種類別セグメンテーションでは、即効性インスリンが2023年に最大の市場シェアを示すと予測されました。

適応症別では、2型糖尿病が2023年の主要セグメントとなりました。

地域別では、北米が2023年の売上高でトップでした。

バイオシミラーインスリン市場：セグメンテーション分析

バイオシミラーインスリンの世界市場は、種類、適応症、流通チャネル、地域に基づいてセグメント化されます。

市場は種類により、持続性 (長時間作用型) インスリン、中間型インスリン、即効性インスリンの3つに分類されます。即効性インスリンの分野が市場を独占しています。この成長の原動力は、食後のグルコース上昇を管理する有効性と、糖尿病患者にとって魅力的なバイオシミラーの費用対効果です。

市場は適応症によって2つのカテゴリーに分けられます：1型糖尿病と2型糖尿病です。2型糖尿病セクターが市場を独占しており、予測期間中もその優位性を維持するとみられます。この背景には、世界的に2型糖尿病の罹患率が上昇していることもあり、バイオシミラーインスリン市場の魅力が高まっています。

バイオシミラーインスリン市場：地域別分析

この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広く分布しています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

バイオシミラーインスリン市場：競合情勢

費用対効果の高い糖尿病治療に対する需要の高まりに後押しされ、メーカー各社は多様な患者ニーズに対応するため製品ポートフォリオを拡充しています。各社は、迅速な承認のために効率的な規制当局への対応に注力する一方、研究開発を強化するために提携や共同研究を採用しています。現地の製薬企業との提携により、新興地域への戦略的な市場参入が可能になり、地域の市場需要に合わせた製品の開発やアクセシビリティの向上により、競争力を高めています。

目次

第1章 バイオシミラーインスリン市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 バイオシミラーインスリンの主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 バイオシミラーインスリン市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 バイオシミラーインスリン市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 バイオシミラーインスリンの市場情勢

  • バイオシミラーインスリンの市場シェア分析 (2023年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 バイオシミラーインスリン市場：種類別

  • 概要
    • セグメント別シェア分析：種類別
    • 持続性インスリン
    • 中間型インスリン
    • 速効性インスリン

第8章 バイオシミラーインスリン市場：適応症別

  • 概要
    • セグメント別シェア分析：適応症別
    • 1型糖尿病
    • 2型糖尿病

第9章 バイオシミラーインスリン市場：流通チャネル別

  • 概要
    • セグメント別シェア分析：流通チャネル別
    • 小売薬局
    • 病院薬局
    • オンライン薬局
    • ドラッグストア

第10章 バイオシミラーインスリン市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：バイオシミラーインスリン業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Eli Lilly and Company
    • BIOTON SA
    • Sanofi SA
    • WOCKHARDT
    • Biocon Ltd.
    • Julphar
    • Tonghua Dongbao
    • Popular Pharmaceuticals Ltd.
    • Polfa Tarchomin SA
    • Advanced Chemical Industries Limited
    • SEDICO Co.
    • Denver Farma SA
    • Aristopharma Ltd.
    • Boehringer Ingelheim
    • NOVO Nordisk A/S
    • Merck &Co.
    • Mylan NV
    • Sandoz
    • Fresenius Kabi
    • Pfizer Inc.
    • BGP Pharma
    • Aspen
    • Others

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4416

REPORT HIGHLIGHT

Biosimilar insulin market size was valued at USD 2,690.87 Million in 2023, expanding at a CAGR of 16.44% from 2024 to 2032.

Biosimilar insulin is a type of insulin product that closely resembles an already approved "reference" insulin in terms of structure, safety, and effectiveness but is typically offered at a lower cost. Developed to treat diabetes, biosimilar insulins undergo rigorous testing to confirm their similarity to existing insulin types, ensuring comparable performance. These products provide diabetic patients with more affordable treatment options, expanding access to vital, life-sustaining insulin therapies globally.

Biosimilar Insulin Market- Market Dynamics

Increasing prevalence of diabetes worldwide to propel market demand

The increasing prevalence of diabetes is driving demand for the global biosimilar insulin market. As investments in diabetes R&D rise and original insulin patents expire, biosimilar insulin is gaining traction. With over 500 million people worldwide affected by diabetes, the need for cost-effective insulin options has soared. However, regulatory challenges and limited clinical acceptance pose barriers to wider adoption in the long term. On the contrary, patent expirations of long-established originator insulin products are expected to drive demand for innovative new biosimilar insulins, creating growth opportunities for manufacturers.

Biosimilar Insulin Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.44% over the forecast period (2024-2032)

Based on type segmentation, fast-acting insulin was predicted to show maximum market share in the year 2023

Based on indication segmentation, diabetes type 2 was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Biosimilar Insulin Market- Segmentation Analysis:

The Global Biosimilar Insulin Market is segmented on the basis of Type, Indication, Distribution Channel, and Region.

The market is divided into three categories based on type: long-acting insulin, intermediate-acting insulin, and fast-acting insulin. The fast-acting insulin sector dominates the market. This growth is driven by its effectiveness in managing postprandial glucose spikes and the cost-effectiveness of biosimilars, appealing to diabetic patients.

The market is divided into two categories based on indication: Diabetes Type 1 and Diabetes Type 2. The diabetes type 2 sector dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to the rising global incidence of type 2 diabetes, which has made the biosimilar insulin market more appealing.

Biosimilar Insulin Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Biosimilar Insulin Market- Competitive Landscape:

Driven by rising demand for cost-effective diabetes treatments, manufacturers are expanding their product portfolios to address diverse patient needs. Companies are focusing on efficient regulatory navigation for faster approvals while adopting partnerships and collaborations to strengthen research, development. Collaborative agreements with local pharmaceutical firms enable strategic market entry in emerging regions, enhancing their competitive edge by tailoring products to regional market demands and improving accessibility.

Recent Developments:

In December 2023, USV and Biogenomics launched INSUQUICK, India's first biosimilar Insulin Aspart, to enhance diabetes care. Developed with 100% indigenous technology, it meets global quality standards through rigorous clinical testing.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILAR INSULIN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • BIOTON S.A.
  • Sanofi SA
  • WOCKHARDT
  • Biocon Ltd.
  • Julphar
  • Tonghua Dongbao
  • Popular Pharmaceuticals Ltd.
  • Polfa Tarchomin S.A
  • Advanced Chemical Industries Limited
  • SEDICO Co.
  • Denver Farma S.A
  • Aristopharma Ltd.
  • Boehringer Ingelheim
  • NOVO Nordisk A/S
  • Merck & Co.
  • Mylan N.V.
  • Sandoz
  • Fresenius Kabi
  • Pfizer Inc.
  • BGP Pharma
  • Aspen
  • Others

GLOBAL BIOSIMILAR INSULIN MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Long-acting Insulin
  • Intermediate-acting Insulin
  • Fast-acting Insulin

GLOBAL BIOSIMILAR INSULIN MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Diabetes Type 1
  • Diabetes Type 2

GLOBAL BIOSIMILAR INSULIN MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Drug Stores

GLOBAL BIOSIMILAR INSULIN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biosimilar Insulin Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilar Insulin Market Snippet by Type
    • 2.1.2. Biosimilar Insulin Market Snippet by Indication
    • 2.1.3. Biosimilar Insulin Market Snippet by Distribution Channel
    • 2.1.4. Biosimilar Insulin Market Snippet by Country
    • 2.1.5. Biosimilar Insulin Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilar Insulin Key Market Trends

  • 3.1. Biosimilar Insulin Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilar Insulin Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilar Insulin Market Opportunities
  • 3.4. Biosimilar Insulin Market Future Trends

4. Biosimilar Insulin Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilar Insulin Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biosimilar Insulin Market Landscape

  • 6.1. Biosimilar Insulin Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilar Insulin Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Long-acting Insulin
    • 7.1.3. Intermediate-acting Insulin
    • 7.1.4. Fast-acting Insulin

8. Biosimilar Insulin Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Diabetes Type 1
    • 8.1.3. Diabetes Type 2

9. Biosimilar Insulin Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies
    • 9.1.5. Drug Stores

10. Biosimilar Insulin Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Biosimilar Insulin Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Biosimilar Insulin Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Biosimilar Insulin Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Biosimilar Insulin Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Biosimilar Insulin Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Biosimilar Insulin Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
    • 11.2.2. BIOTON S.A.
    • 11.2.3. Sanofi SA
    • 11.2.4. WOCKHARDT
    • 11.2.5. Biocon Ltd.
    • 11.2.6. Julphar
    • 11.2.7. Tonghua Dongbao
    • 11.2.8. Popular Pharmaceuticals Ltd.
    • 11.2.9. Polfa Tarchomin S.A
    • 11.2.10. Advanced Chemical Industries Limited
    • 11.2.11. SEDICO Co.
    • 11.2.12. Denver Farma S.A
    • 11.2.13. Aristopharma Ltd.
    • 11.2.14. Boehringer Ingelheim
    • 11.2.15. NOVO Nordisk A/S
    • 11.2.16. Merck & Co.
    • 11.2.17. Mylan N.V.
    • 11.2.18. Sandoz
    • 11.2.19. Fresenius Kabi
    • 11.2.20. Pfizer Inc.
    • 11.2.21. BGP Pharma
    • 11.2.22. Aspen
    • 11.2.23. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us